Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination With Trametinib in KRAS-mutant Pancreatic and Colorectal Cancer

Cancer Research - United States
doi 10.1158/0008-5472.can-18-2861
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination With Vorinostat in KRAS-Mutant Colorectal Cancer Models

Clinical Cancer Research
Cancer ResearchOncology
2011English

LY3009120, a panRAF Inhibitor, Has Significant Anti-Tumor Activity in BRAF and KRAS Mutant Preclinical Models of Colorectal Cancer

Oncotarget
Oncology
2016English

Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance.

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2018English

Preclinical Efficacy of the Novel Competitive NAMPT Inhibitor STF-118804 in Pancreatic Cancer

Oncotarget
Oncology
2017English

Combination PI3K/MEK Inhibition Promotes Tumor Apoptosis and Regression in PIK3CA Wild-Type, KRAS Mutant Colorectal Cancer

Cancer Letters
Cancer ResearchOncology
2014English

Allosteric Inhibitors Target KRAS in a Mutant-Specific Manner

Cancer Discovery
Oncology
2013English

Safety and Efficacy of the Addition of Simvastatin to Cetuximab in Previously Treated KRAS Mutant Metastatic Colorectal Cancer Patients

Investigational New Drugs
OncologyPharmacology
2015English

New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer

Clinical Cancer Research
Cancer ResearchOncology
2010English

Trametinib With and Without Pazopanib Has Potent Preclinical Activity in Thyroid Cancer

Oncology Reports
MedicineCancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy